(R)-3-O-Methyldopa-d3

Modify Date: 2024-04-03 10:32:22

(R)-3-O-Methyldopa-d3 structure	Common Name	(R)-3-O-Methyldopa-d3
	CAS Number	1259947-39-1	Molecular Weight	214.23
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₀H₁₀D₃NO₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of (R)-3-O-Methyldopa-d3

(R)-3-O-Methyldopa-d3 is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

Name	(R)-3-O-Methyldopa-d3

Description	(R)-3-O-Methyldopa-d3 is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Asanuma M, Miyazaki I. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA. BMC Neurosci. 2016 Jul 25;17(1):52.

Molecular Formula	C₁₀H₁₀D₃NO₄
Molecular Weight	214.23

(R)-3-O-Methyldopa-d3

Use of (R)-3-O-Methyldopa-d3

Names

(R)-3-O-Methyldopa-d3 Biological Activity

Chemical & Physical Properties